NEUROCRINE BIOSCIENCES, INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT02349503
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 234
- Registration Number
- NCT02274558
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 36
- Registration Number
- NCT02256475
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Biological: VY-AADC01
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT01973543
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
Phase 1
Completed
- Conditions
- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
- Interventions
- Drug: NBI-98854 50 mg capsule
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT01916993
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Lakewood, Colorado, United States
🇺🇸Davita Clinical Research, Minneapolis, Minnesota, United States
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects
Phase 1
Completed
- Conditions
- Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
- Interventions
- Drug: NBI-98854 50 mg capsule once daily
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT01910480
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 102
- Registration Number
- NCT01733121
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 109
- Registration Number
- NCT01688037
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 37
- Registration Number
- NCT01393600
- Locations
- 🇺🇸
Woodland International Research Group, Inc, Little Rock, Arkansas, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Synergy Clinical Research, National City, California, United States
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 10
- Registration Number
- NCT01267188
© Copyright 2025. All Rights Reserved by MedPath